Azenta

AZTA

Market cap $1.4B

BURLINGTON, Mass. , Oct. 15, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that it will host an Investor Day on Wednesday, December 10, 2025, at the Company's biorepository facility in Indianapolis, Indiana.

Azenta, Inc. (NASDAQ:AZTA ) Q3 2025 Earnings Conference Call August 6, 2025 8:30 AM ET Company Participants John P. Marotta - President, CEO & Director Lawrence Y.

Azenta (AZTA) Q3 EPS Jumps 36%

BURLINGTON, Mass. , Aug. 5, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today reported financial results for the third quarter ended June 30, 2025.

BURLINGTON, Mass. , July 31, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that it has entered a collaboration with Frenova, a division of Fresenius Medical Care, and Nephronomics, a Renal Precision Medicine company, to begin genomic sequencing and data generation for Frenova's transformative MyReason® genomics research program.

Frenova and Nephronomics, a renal precision company co-founded by Fresenius Medical Care, initiate collaboration with GENEWIZ by Azenta Life Sciences Provides vital insights through sophisticated genomic sequencing and analysis of Frenova's My Reason® genomic and clinical data registry Paves way for advances in precision kidney disease care, novel therapies, and diagnostics BAD HOMBURG, Germany , July 31, 2025 /PRNewswire/ -- Fresenius Medical Care today announced that Frenova, the company's third-party clinical research organization, along with Nephronomics, a renal precision medicine company, and GENEWIZ by Azenta Life Sciences, have entered a collaboration to advance the genomic analysis efforts for Frenova's transformative My Reason® genomics research program. This strategic collaboration aims to leverage cutting-edge technologies to better understand kidney, cardiovascular, and metabolic diseases while driving advancements in precision medicine for patients worldwide.

BURLINGTON, Mass. , July 30, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in the 10th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference, on Tuesday, August 12, 2025.

BURLINGTON, Mass. , July 23, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal third quarter 2025 earnings which ended on June 30, 2025, on Tuesday August 5, 2025, before the market opens.

Integrated solution aims to reduce time and cost to lead candidates, advancing safer and more effective gene therapies to patients faster. BURLINGTON, Mass.

Azenta, Inc. (NASDAQ:AZTA ) Q2 2025 Earnings Conference Call May 7, 2025 8:30 AM ET Company Participants Yvonne Perron - Vice President, Financial Planning & Analysis and Investor Relations John Marotta - President and Chief Executive Officer Lawrence Lin - Chief Financial Officer Conference Call Participants David Saxon - Needham & Company, LLC Vijay Kumar - Evercore Inc. Paul Knight - KeyBanc Capital Markets Inc. Matthew Stanton - Jefferies Group LLC Brendan Smith - TD Cowen Operator Greetings, and welcome to the Azenta Q2 2025 Financial Results. During the presentation, all participants will be in a listen-only mode.